{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:19:38Z","timestamp":1792160378438,"version":"4.4.0"},"reference-count":133,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) represents the disease prototype of genetically based diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR::ABL1 fusion protein, exemplify the success of molecularly based therapy. Most patients now have long-term survival; however, TKI resistance is a persistent clinical problem. TKIs are effective in the BCR::ABL1-driven chronic phase of CML but are relatively ineffective for clinically defined advanced phases. Genomic investigation of drug resistance using next-generation sequencing for CML has lagged behind other hematological malignancies. However, emerging data show that genomic abnormalities are likely associated with suboptimal response and drug resistance. This has already been supported by the presence of BCR::ABL1 kinase domain mutations in drug resistance, which led to the development of more potent TKIs. Next-generation sequencing studies are revealing additional mutations associated with resistance. In this review, we discuss the initiating chromosomal translocation that may not always be a straightforward reciprocal event between chromosomes 9 and 22 but can sometimes be accompanied by sequence deletion, inversion, and rearrangement. These events may biologically reflect a more genomically unstable disease prone to acquire mutations. We also discuss the future role of cancer-related gene mutation analysis for risk stratification in CML.<\/jats:p>","DOI":"10.3390\/cancers14030620","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T11:02:53Z","timestamp":1643194973000},"page":"620","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5375-9334","authenticated-orcid":false,"given":"Adelina","family":"Fernandes","sequence":"first","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide 5000, Australia"},{"name":"School of Medicine, University of Adelaide, Adelaide 5000, Australia"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide 5000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naranie","family":"Shanmuganathan","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide 5000, Australia"},{"name":"School of Medicine, University of Adelaide, Adelaide 5000, Australia"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide 5000, Australia"},{"name":"Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide 5000, Australia"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide 5000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-7981","authenticated-orcid":false,"given":"Susan","family":"Branford","sequence":"additional","affiliation":[{"name":"Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide 5000, Australia"},{"name":"School of Medicine, University of Adelaide, Adelaide 5000, Australia"},{"name":"Precision Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide 5000, Australia"},{"name":"School of Pharmacy and Medical Science, University of South Australia, Adelaide 5000, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1038\/s41375-021-01436-6","article-title":"HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions","volume":"35","author":"Bruford","year":"2021","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_4","unstructured":"(2022, January 02). NCCN Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 2.2022. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1427."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.0954-6820.1986.tb02760.x","article-title":"Clinical Findings and Prognostic Factors in Chronic Myeloid Leukemias","volume":"220","author":"Wedelin","year":"2009","journal-title":"Acta Med. Scand."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of Chronic Myelogenous Leukemia in Mice by the P210 bcr\/abl Gene of the Philadelphia Chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","article-title":"ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients with Up-Front Cytogenetic Resistance to Imatinib Are Associated with a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"23","author":"Soverini","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate\u2013binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","article-title":"BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study","volume":"359","author":"Schneller","year":"2002","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Soenen","year":"2002","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/sj.leu.2404236","article-title":"Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: A retrospective analysis from the French intergroup of CML (Fi(\u03d5)-LMC GROUP)","volume":"20","author":"Nicolini","year":"2006","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Thomas","year":"2008","journal-title":"Haematologica"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: Does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2009-04-219410","article-title":"Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation","volume":"114","author":"Nicolini","year":"2009","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3324\/haematol.2012.080234","article-title":"The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis","volume":"98","author":"Nicolini","year":"2013","journal-title":"Haematologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance","volume":"16","author":"Shakespeare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2008.16.9953","article-title":"Finding of Kinase Domain Mutations in Patients with Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression","volume":"26","author":"Khorashad","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3324\/haematol.2010.039321","article-title":"Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy","volume":"96","author":"Kantarjian","year":"2011","journal-title":"Haematologica"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/S2352-3026(19)30027-4","article-title":"Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: A population-based study","volume":"6","author":"Kizilors","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1182\/blood-2011-08-375535","article-title":"Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile","volume":"119","author":"Parker","year":"2012","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2015-09-666214","article-title":"The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib","volume":"127","author":"Parker","year":"2016","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.2011.35.0934","article-title":"Sensitive Detection of BCR-ABL1 Mutations in Patients with Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy","volume":"29","author":"Parker","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: The NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"21982","DOI":"10.18632\/oncotarget.8010","article-title":"Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients","volume":"7","author":"Soverini","year":"2016","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"Polakova","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/10428194.2018.1473573","article-title":"Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors","volume":"60","author":"Erbilgin","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41408-021-00420-8","article-title":"Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice","volume":"11","author":"Luna","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Mauro","year":"2021","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","article-title":"Targeting Bcr\u2013Abl by combining allosteric with ATP-binding-site inhibitors","volume":"463","author":"Zhang","year":"2010","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Lindstr\u00f6m, H.J.G., and Friedman, R. (2020). The effects of combination treatments on drug resistance in chronic myeloid leukaemia: An evaluation of the tyrosine kinase inhibitors axitinib and asciminib. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06782-9"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood-2021-149225","article-title":"A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults","volume":"138","author":"Luskin","year":"2021","journal-title":"Blood"},{"key":"ref_50","first-page":"4470","article-title":"Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 (T315I)-compound mutations","volume":"11","author":"Gleixner","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/leu.2016.353","article-title":"Identification and characterization of activating ABL1 1b kinase mutations: Impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors","volume":"31","author":"Lee","year":"2016","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2141.2002.03508.x","article-title":"Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene","volume":"117","author":"Branford","year":"2002","journal-title":"Br. J. Haematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","article-title":"The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview","volume":"33","author":"Baccarani","year":"2019","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood.V76.9.1819.1819","article-title":"New type of Bcr\/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"76","author":"Saglio","year":"1990","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-009-0822-7","article-title":"Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts","volume":"89","author":"Sharma","year":"2009","journal-title":"Ann. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e2020062","DOI":"10.4084\/mjhid.2020.062","article-title":"Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia","volume":"12","author":"Molica","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620716657994","article-title":"Current developments in molecular monitoring in chronic myeloid leukemia","volume":"7","author":"Marum","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2141.1995.tb08362.x","article-title":"Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: No correlation with clinical features, cytogenetic response, duration of chronic phase, or survival","volume":"89","author":"Shepherd","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V70.2.448.448","article-title":"CML patients in blast crisis have breakpoints localized to a specific region of the BCR","volume":"70","author":"Dudek","year":"1987","journal-title":"Blood"},{"key":"ref_60","first-page":"1648","article-title":"Chronic myeloid-leukemia, BCR\/ABL transcript, response to alpha-interferon and survival","volume":"9","author":"Baccarani","year":"1995","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ajh.24774","article-title":"The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib","volume":"92","author":"Castagnetti","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clml.2017.06.009","article-title":"Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib","volume":"17","author":"Pagnano","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4238\/vol7-4gmr485","article-title":"Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr\/Abl fusion transcripts","volume":"7","author":"Polampalli","year":"2008","journal-title":"Genet. Mol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1182\/blood-2015-10-674242","article-title":"Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors","volume":"127","author":"Jain","year":"2016","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.18632\/oncotarget.23691","article-title":"Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib","volume":"9","author":"Breccia","year":"2017","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cncr.31977","article-title":"The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors","volume":"125","author":"Farina","year":"2019","journal-title":"Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.3324\/haematol.2017.168740","article-title":"E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy","volume":"102","author":"Claudiani","year":"2017","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: Results of the EPIC study","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1600-0609.2008.01053.x","article-title":"Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia","volume":"80","author":"Greiner","year":"2008","journal-title":"Eur. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e2020066","DOI":"10.4084\/mjhid.2020.066","article-title":"Treatment-free remission in Chronic Myeloid Leukemia harboring atypical BCR-ABL1 transcripts","volume":"12","author":"Dragani","year":"2020","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1080\/10428194.2020.1772476","article-title":"Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia","volume":"61","author":"Pagani","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_75","first-page":"565","article-title":"Complex translocations, simple variant translocations and Ph-negative cases in chronic myelogenous leukaemia","volume":"85","author":"Huret","year":"1990","journal-title":"Qual. Life Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cancergencyto.2006.10.006","article-title":"On the genesis and prognosis of variant translocations in chronic myeloid leukemia","volume":"173","author":"Gorusu","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: Molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0165-4608(91)90145-K","article-title":"Complex chromosomal translocations in the Philadelphia chromosome leukemias: Serial translocations or a concerted genomic rearrangement?","volume":"57","author":"Fitzgerald","year":"1991","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0165-4608(03)00128-6","article-title":"Genesis of variant philadelphia chromosome translocations in chronic myelocytic leukemia","volume":"147","author":"Naumann","year":"2003","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-4608(94)90083-3","article-title":"Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysis","volume":"78","author":"Calabrese","year":"1994","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0165-4608(85)90086-X","article-title":"Variant Ph translocations in chronic myeloid leukemia","volume":"18","author":"Heim","year":"1985","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V95.3.738.003k21_738_743","article-title":"Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia","volume":"95","author":"Sinclair","year":"2000","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2141.2004.04899.x","article-title":"Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome","volume":"125","author":"Kantarjian","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V98.6.1732","article-title":"Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia","volume":"98","author":"Huntly","year":"2001","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cancergencyto.2009.05.010","article-title":"Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: Genesis and deletion of derivative chromosome 9","volume":"194","author":"Bennour","year":"2009","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2141.2003.04291.x","article-title":"Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukaemia","volume":"121","author":"Reid","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bjc.1981.146","article-title":"Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia","volume":"44","author":"Potter","year":"1981","journal-title":"Br. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clml.2016.09.007","article-title":"Predictive and Prognostic Implications of Variant Philadelphia Translocations in CML: Experience from a Tertiary Oncology Center in Southern India","volume":"17","author":"Kanakasetty","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00277-012-1598-8","article-title":"Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome","volume":"92","author":"Koshiyama","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: Long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4274\/tjh.2015.0237","article-title":"The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia","volume":"33","author":"Bozkurt","year":"2016","journal-title":"Turk. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cancergencyto.2008.01.005","article-title":"Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy","volume":"182","author":"Richebourg","year":"2008","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/02841861003660031","article-title":"Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors","volume":"49","author":"Stagno","year":"2010","journal-title":"Acta Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3892\/ol.2010.180","article-title":"Insertion of the 3\u2032 ABL region into the long arm of chromosome 1 in a Philadelphia chromosome-negative chronic myeloid leukemia case","volume":"1","author":"Liehr","year":"2010","journal-title":"Oncol. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1023\/A:1008349405763","article-title":"Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization","volume":"10","author":"Seong","year":"1999","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.1987.tb06915.x","article-title":"Ph-negative chronic myeloid leukaemia","volume":"66","author":"Fitzgerald","year":"1987","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V73.4.1038.1038","article-title":"Cytogenetic and molecular analysis in Philadelphia negative CML","volume":"73","author":"Hermans","year":"1989","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1755-8166-1-14","article-title":"FISH mapping of Philadelphia negative BCR\/ABL1 positive CML","volume":"1","author":"Virgili","year":"2008","journal-title":"Mol. Cytogenet."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood-2003-01-0123","article-title":"Double jeopardy from a single translocation: Deletions of the derivative chromosome 9 in chronic myeloid leukemia","volume":"102","author":"Huntly","year":"2003","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5085","DOI":"10.1002\/cncr.26147","article-title":"Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Cancer"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"697009","DOI":"10.3389\/fgene.2021.697009","article-title":"Genomic Copy Number Variants in CML Patients with the Philadelphia Chromosome (Ph+): An Update","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Genet."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/blood.V97.11.3581","article-title":"Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis","volume":"97","author":"Kolomietz","year":"2001","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1182\/blood-2004-06-2208","article-title":"Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia","volume":"105","author":"Kantarjian","year":"2005","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1200\/JCO.2009.26.7963","article-title":"Deletions of the Derivative Chromosome 9 Do Not Influence the Response and the Outcome of Chronic Myeloid Leukemia in Early Chronic Phase Treated with Imatinib Mesylate: GIMEMA CML Working Party Analysis","volume":"28","author":"Castagnetti","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5045\/br.2018.53.2.152","article-title":"The incidence of atypical patterns ofBCR-ABL1rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML)","volume":"53","author":"Horvat","year":"2018","journal-title":"Blood Res."},{"key":"ref_108","first-page":"558","article-title":"The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia","volume":"90","author":"Bacher","year":"2005","journal-title":"Haematologica"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cancergencyto.2007.01.012","article-title":"Incidence of submicroscopic deletions vary according to disease entities and chromosomal translocations in hematologic malignancies: Investigation by fluorescence in situ hybridization","volume":"175","author":"Moon","year":"2007","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41375-019-0546-1","article-title":"Cryptic genomic lesions in adverse-risk acute myeloid leukemia identified by integrated whole genome and transcriptome sequencing","volume":"34","author":"Kim","year":"2019","journal-title":"Leukemia"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cancergen.2017.09.001","article-title":"Next-generation sequencing and molecular cytogenetic characterization of ETV6-LYN fusion due to chromosomes 1, 8 and 12 rearrangement in acute myeloid leukemia","volume":"218-219","author":"Ma","year":"2017","journal-title":"Cancer Genet."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cancergencyto.2004.11.006","article-title":"Cryptic chromosomal anomaly in a patient with acute myeloid leukemia leading to AML1\/ETO fusion with unfavorable prognostic factors","volume":"160","author":"Ishii","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ng.3230","article-title":"The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias","volume":"47","author":"Andersson","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e27266","DOI":"10.1002\/pbc.27266","article-title":"Relatively favorable prognosis for MLL -rearranged childhood acute leukemia with reciprocal translocations","volume":"65","author":"Yang","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"eaam8419","DOI":"10.1126\/science.aam8419","article-title":"Rearrangement bursts generate canonical gene fusions in bone and soft tissue tumors","volume":"361","author":"Anderson","year":"2018","journal-title":"Science"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ccr.2013.04.025","article-title":"Chromoplexy: A New Category of Complex Rearrangements in the Cancer Genome","volume":"23","author":"Shen","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cell.2013.03.021","article-title":"Punctuated Evolution of Prostate Cancer Genomes","volume":"153","author":"Baca","year":"2013","journal-title":"Cell"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Awad","year":"2020","journal-title":"Blood Adv."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.2147\/OTT.S257661","article-title":"Integrative Genomic Analysis Reveals Cancer-Associated Gene Mutations in Chronic Myeloid Leukemia Patients with Resistance or Intolerance to Tyrosine Kinase Inhibitor","volume":"13","author":"Wu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2020004834","article-title":"An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia","volume":"135","author":"Ko","year":"2020","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3324\/haematol.2017.179937","article-title":"De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways","volume":"104","author":"Magistroni","year":"2019","journal-title":"Haematologica"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1615\/CritRevOncog.v16.i1-2.80","article-title":"RUNX1 Mutations in Clonal Myeloid Disorders: From Conventional Cytogenetics to Next Generation Sequencing, A Story 40 Years in the Making","volume":"16","author":"Mangan","year":"2011","journal-title":"Crit. Rev. Oncog."},{"key":"ref_124","first-page":"1817","article-title":"Biallelic and Heterozygous Point Mutations in the Runt Domain of the AML1\/PEBP2\u03b1 B Gene Associated with Myeloblastic Leukemias","volume":"93","author":"Osato","year":"1999","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","article-title":"RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses","volume":"35","author":"Awad","year":"2020","journal-title":"Leukemia"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","article-title":"Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia","volume":"25","author":"Marceau","year":"2011","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/10428194.2021.1894652","article-title":"Mutational landscape of chronic myeloid leukemia: More than a single oncogene leukemia","volume":"62","author":"Kankainen","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2021-150020","article-title":"Correlations between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy","volume":"138","author":"Zhang","year":"2021","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1182\/blood-2021-154273","article-title":"Mutational Profiles during the Progression of Chronic Myeloid Leukemia","volume":"138","author":"Xue","year":"2021","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1038\/s41375-020-0751-y","article-title":"Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia","volume":"34","author":"Thomson","year":"2020","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/620\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:08:20Z","timestamp":1760134100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":133,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030620"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030620","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]}}}